In a Victory for the Free Market, FDA Approves New Schizophrenia Drug
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...
devdiscourse11m
Dow Jones Hits Record High Amid Hopes for Fed Rate Cuts
The Dow Jones Industrial Average reached a record high following a modest inflation report, spurring hopes for additional ...
Honolulu Star-Advertiser21m
Dow closes at record high on tame inflation report
The blue-chip Dow Jones Industrial Average closed at a record high today as investors welcomed a subdued inflation report ...
LancasterOnline21m
Stock market today: Dow sets a record as Wall Street drifts to the finish of another winning week
U.S. stocks closed another record-setting week with a muted performance. The S&P 500 edged down by 0.1% Friday from its ...
health.wusf.usf.edu25m
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
Becker's Hospital Review31m
FDA approves schizophrenia treatment
The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...
The Register-Herald43m
Stock market today: Dow ekes out a record while weakness in tech pulls other indexes lower
The Dow Jones Industrial Average edged up to another record high while declines in tech stocks pulled other indexes lower.
devdiscourse51m
Dow Jones Closes at Record High as Investors Celebrate Subdued Inflation Report
The Dow Jones Industrial Average closed at a record high, driven by investor optimism following a subdued inflation report.
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The ...
Bristol Myers Squibb's COBENFY Gains FDA Approval For Adult Schizophrenia Treatment
Bristol Myers Squibb (BMY) announced that the U.S. Food and Drug Administration has approved COBENFY (xanomeline and trospium ...
The Washington Post22h
FDA approves a novel drug for schizophrenia, a potential ‘game changer’
The new drug, Bristol Myers Squibb’s Cobenfy, targets a different area of the brain than traditional antipsychotic drugs to ...
FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades
The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S. living with ...